Evolus, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Evolus, Inc., a Delaware corporation, on May 29, 2018. The report discloses the appointment of a new senior executive officer effective on the date of the report.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the appointment of Lauren Silvernail as Chief Financial Officer and Executive Vice President, Corporate Development, effective May 29, 2018.
Management Commentary and Compensation Details
Ms. Silvernail brings extensive experience from Revance Therapeutics, ISTA Pharmaceuticals, and Allergan. Her employment agreement includes the following terms:
- Base Salary: $425,000 annualized.
- Relocation: One-time payment of $25,000.
- Annual Bonus: Target of 40% of base salary, subject to performance metrics.
- Equity Awards:
- Option to purchase 200,000 shares at an exercise price of $22.44 per share.
- Grant of 30,000 Restricted Stock Units (RSUs).
- Severance Provisions:
- Standard Termination (without Cause/Good Reason): 6 months salary continuation, pro-rata bonus, and pro-rata equity vesting.
- Change in Control Termination: 12 months lump-sum salary, pro-rata bonus, and full acceleration of equity vesting.
Investor Verification Checklist
- Verify the full text of the Employment Agreement filed as an exhibit to the subsequent Form 10-Q for the quarter ended June 30, 2018.
- Confirm the vesting schedule details for the 200,000 stock options and 30,000 RSUs granted under the 2017 Omnibus Incentive Plan.
- Review the press release (Exhibit 99.1) for additional context on the leadership transition.